Trial Information

Summary: Hot Flashes Among Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: Psychosocial and Quality of Life Issues.

Researchers at the University of Pennsylvania are studying quality of life issues that arise in men with prostate cancer who are undergoing androgen deprivation therapy (ADT), such as lupron and zoladex. They are interested in changes in sleep pattern, energy level and overall wellbeing, but are particularly focusing on hot flashes. Nearly 80% of men complain about hot flashes in clinic based on prior research findings. This study will establish the severity and frequency of hot flashes among prostate cancer patients and help to better understand their impact on quality of life.

Participants may be compensated up to $225.

Inclusion / Exclusion Criteria:
In order to be eligible to participate in the study, a patient must be:

• Over the age of 18
• Diagnosed with prostate cancer
• Currently receiving Androgen Deprivation Therapy (ADT)
• Able to consent for self and can speak, read, and understand English without the aid of an interpreter.

Exclusion factors include:

• Chemotherapy
• Radiation treatment
• Myelosuppressive therapies
• Bedridden due to medical comorbidity or disability unrelated to prostate cancer

For more information,

If you would like to learn more about participating in this study, please send an e-mail message using the form below.